share_log
Reuters ·  May 9 07:08
Bluebird bio Inc - Anticipates Recognizing Revenue From Its First Infusion of Lyfgenia in Q3 of 2024
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment